4.7 Review

Phytochemicals as Potential Chemopreventive and Chemotherapeutic Agents for Emerging Human Papillomavirus-Driven Head and Neck Cancer: Current Evidence and Future Prospects

Journal

FRONTIERS IN PHARMACOLOGY
Volume 12, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.699044

Keywords

head and neck cancer; human pappillomavirus; tobacco; smoking; phytochemicals; therapeutics; prevention

Funding

  1. Central Council for Research in Homeopathy, Department of AYUSH, Government of India [17-51/2016-17/CCRH/Tech/Coll./DU-Cervical Cancer.4850]
  2. Department of Science and Technology-SERB, India [EMR/2017/004018/BBM]
  3. Indian Council of Medical Research [5/13/38/2014 NCDIII-Eoffice73143]
  4. Council of Scientific and Industrial Research (CSIR) [09/045 (1,622)/2018-EMR-I, 09/045 (1,629)/2019-EMR-I, 15/12/2019 (ii) EU-V]
  5. University Grants Commission (UGC) [573/(CSIR-UGC NET JUNE 2017), 764/(CSIR-UGC NET JUNE 2019)]
  6. ICMR, India [5/13/38/2014 NCDIII-Eoffice73143]
  7. CCRH, India [17-51/2016-17/CCRH/Tech/Coll./DU-Cervical Cancer.4850]

Ask authors/readers for more resources

Head and neck cancer usually originates from squamous cells of the upper aerodigestive tract, with an increasing proportion of HPV-positive cases. Pre-therapy assessment of HPV status is necessary, and phytochemicals show potential in HNC treatment but lack specific treatment for HPV.
Head and neck cancer (HNC) usually arises from squamous cells of the upper aerodigestive tract that line the mucosal surface in the head and neck region. In India, HNC is common in males, and it is the sixth most common cancer globally. Conventionally, HNC attributes to the use of alcohol or chewing tobacco. Over the past four decades, portions of human papillomavirus (HPV)-positive HNC are increasing at an alarming rate. Identification based on the etiological factors and molecular signatures demonstrates that these neoplastic lesions belong to a distinct category that differs in pathological characteristics and therapeutic response. Slow development in HNC therapeutics has resulted in a low 5-year survival rate in the last two decades. Interestingly, HPV-positive HNC has shown better outcomes following conservative treatments and immunotherapies. This raises demand to have a pre-therapy assessment of HPV status to decide the treatment strategy. Moreover, there is no HPV-specific treatment for HPV-positive HNC patients. Accumulating evidence suggests that phytochemicals are promising leads against HNC and show potential as adjuvants to chemoradiotherapy in HNC. However, only a few of these phytochemicals target HPV. The aim of the present article was to collate data on various leading phytochemicals that have shown promising results in the prevention and treatment of HNC in general and HPV-driven HNC. The review explores the possibility of using these leads against HPV-positive tumors as some of the signaling pathways are common. The review also addresses various challenges in the field that prevent their use in clinical settings.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available